Charts

News

28 Mar, 2024
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted ...
20 Mar, 2024
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. The company's ...
19 Mar, 2024
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's market cap ...
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”). The Reverse Split was previously approved by
01 Mar, 2024
Longeveron ( NASDAQ:LGVN ) Full Year 2023 Results Key Financial Results Net loss: US$22.2m (loss widened by 18% from FY...
28 Feb, 2024
Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript February 27, 2024 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.21. FDS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon, and […]
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) released its full year 2023 results and issued a business update, which included announcements that we believe sets the company up for a better chance of success: • Management announced that the company was devoting more of its focus to the pursuit of FDA approval of Lomecel-B for the treatment of HLHS.
27 Feb, 2024
21:40
FinancialContent
Longeveron (NASDAQ:LGVN) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:00 PM. Here's what investors need to know ...
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Announced Additional Validating Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mi
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on ...
26 Feb, 2024
21:00
FinancialContent
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know ...
21 Feb, 2024
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on February 27, 2024. The Company will host a conference call at 5:00 p.m. ET that day to discuss the Company’s results and provide a business update. TitleLongeveron Full Year 2023 Results Conference CallDate2/27/2
13 Feb, 2024
BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic ...
31 Jan, 2024
Gainers SINTX Techs (NASDAQ:SINT) shares moved upwards by 79.8% to $0.42 during Wednesday's pre-market session. The company's market ...
30 Jan, 2024
Gainers NexImmune (NASDAQ:NEXI) stock increased by 152.8% to $23.51 during Tuesday's regular session. The company's market cap stands ...
29 Jan, 2024
Gainers OneMedNet (NASDAQ:ONMD) stock rose 172.1% to $1.39 during Monday's pre-market session. The market value of their outstanding ...
U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions , today announces it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for
03 Jan, 2024
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence ...
22 Dec, 2023
MIAMI, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,355,301 shares of its
21 Dec, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow ...
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly ...
Gainers HOOKIPA Pharma (NASDAQ:HOOK) stock moved upwards by 73.2% to $0.98 during Thursday's regular session. The market value of their ...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded ...
MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.74
Longeveron Inc (NASDAQ: LGVN) shares are trading lower by 22.8% to $1.25 Thursday morning after the companyhas finalized an ...
MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62
20 Dec, 2023
New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated patientsMRI Biomarker study data showed that Lomecel-B™ countered loss of brain volume in multiple areas associated with Alzheimer’s disease, reduced brain neuroinflammation and improved cerebral blood flow Overall results confirmed the drug product’s therapeutic potential in the treatment of mild Alzheime
05 Dec, 2023
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions ...
14 Nov, 2023
LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel
11 Nov, 2023
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing in Phase 2 ELPIS II trial - MIAMI, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syn
Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript November 10, 2023 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. Operator: Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal […]
10 Nov, 2023
Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association $4 Million in Equity Financing Secured in Registered Direct Offering ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Compan
Companies Reporting Before The Bell • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. • ...
11:09
Yahoo! Finance
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of 2,424,243 shares and
09 Nov, 2023
14:01
FinancialContent
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2023-11-10. Here's what investors need to know ...
03 Nov, 2023
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial results prior to the market open on Friday November 10, 2023. The Company will host a conference call and webcast that day to discuss the results, and provide an update on its clinical programs and corp
24 Oct, 2023
LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points
13 Oct, 2023
MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 2,424,243 shares of its
12 Oct, 2023
MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock (“common stock"), or
14 Aug, 2023
11 Aug, 2023
14:57
Seeking Alpha
20 Jul, 2023
10 Apr, 2023
28 Feb, 2023
09 Oct, 2022
14 Sep, 2022

Related Articles